Efficacy and prognosis of Baofukang suppository combined with recombinant human interferon α-2b in the treatment of chronic cervicitis with HPV infection

Abstract

Objective To study the clinical efficacy of Baofukang suppository and recombinant human interferon α-2b in the treatment of HPV infection with chronic cervicitis, and to observe the prognosis, thus to provide reference for its clinical treatment. Methods 120 patients with chronic cervicitis with HPV infection were selected.All patients were divided into observation group and control group by random number table method, 60 cases in each group.The observation group was treated with Baofukang combined with recombinant human interferon α-2b, and the control group was treated with recombinant human interferon α-2b.The patients were evaluated before treatment, at the end of treatment and 3 months after treatment.The cure rate, total effective rate, recurrence rate, incidence rate of adverse reactions were observed and compared. Results In the observation group, 26 cases were cured, the cure rate was 43.33%.In the control group, 15 cases were cured, the cure rate was 25%.The cure rate of the observation group was higher than that of the control group, the difference was statistically significant(χ2=4.482, P 0.05). After treatment for 3 months, the recurrence rate was 0.00% in the observation group and 1.67% in the control group, the difference was not statistically significant(χ2=1.008, P>0.05). Conclusion The combination of Baofukang suppository and recombinant human interferon α-2b showed good curative effect and prognosis in the treatment of chronic cervicitis with HPV infection, and it is worthy to be popularized in clinical practice. Key words: Uterine cervicitis; Human papillomavirus; Baofukang suppository; Recominant human interferon α-2b